These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27240645)

  • 1. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.
    Mughal TI; Abdel-Wahab O; Rampal R; Mesa R; Koschmieder S; Levine R; Hehlmann R; Saglio G; Barbui T; Van Etten RA
    Leuk Lymphoma; 2016 Jul; 57(7):1517-26. PubMed ID: 27240645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
    Mughal TI; Gotlib J; Mesa R; Koschmieder S; Khoury HJ; Cortes JE; Barbui T; Hehlmann R; Mauro M; Saussele S; Radich JP; Van Etten RA; Saglio G; Verstovek S; Gale RP; Abdel-Wahab O
    Leuk Res; 2018 Apr; 67():67-74. PubMed ID: 29466766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
    Van Etten RA; Mauro M; Radich JP; Goldman JM; Saglio G; Jamieson C; Soverini S; Gambacorti-Passerini C; Hehlmann R; Martinelli G; Perrotti D; Scadden DT; Skorski T; Tefferi A; Mughal TI
    Leuk Lymphoma; 2013 Jun; 54(6):1151-8. PubMed ID: 23121619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
    Yung Y; Lee E; Chu HT; Yip PK; Gill H
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
    Mughal TI; Pemmaraju N; Psaila B; Radich J; Bose P; Lion T; Kiladjian JJ; Rampal R; Jain T; Verstovsek S; Yacoub A; Cortes JE; Mesa R; Saglio G; van Etten RA
    Hematol Oncol; 2020 Dec; 38(5):654-664. PubMed ID: 32592408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.
    Mughal TI; Barbui T; Abdel-Wahab O; Kralovics R; Jamieson C; Kvasnicka HM; Mullaly A; Rampal R; Mesa R; Kiladjian JJ; Deininger M; Prchal J; Hehlmann R; Saglio G; Van Etten RA
    Leuk Lymphoma; 2015 Jul; 56(7):1938-48. PubMed ID: 25330439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    Shimoda K; Takahashi N; Kirito K; Iriyama N; Kawaguchi T; Kizaki M
    Int J Hematol; 2020 Sep; 112(3):268-291. PubMed ID: 32783166
    [No Abstract]   [Full Text] [Related]  

  • 9. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
    Masarova L; Bose P; Verstovsek S
    Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
    Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
    Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
    Saglio G; Jabbour E
    Leuk Lymphoma; 2018 Jul; 59(7):1523-1538. PubMed ID: 28972424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
    Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
    Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
    Osman AEG; Deininger MW
    Blood Rev; 2021 Sep; 49():100825. PubMed ID: 33773846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
    Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W
    Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
    Baccarani M; Abruzzese E; Accurso V; Albano F; Annunziata M; Barulli S; Beltrami G; Bergamaschi M; Binotto G; Bocchia M; Caocci G; Capodanno I; Cavazzini F; Cedrone M; Cerrano M; Crugnola M; D'Adda M; Elena C; Fava C; Fazi P; Fozza C; Galimberti S; Giai V; Gozzini A; Gugliotta G; Iurlo A; La Barba G; Levato L; Lucchesi A; Luciano L; Lunghi F; Lunghi M; Malagola M; Marasca R; Martino B; Melpignano A; Miggiano MC; Montefusco E; Musolino C; Palmieri F; Pregno P; Rapezzi D; Rege-Cambrin G; Rupoli S; Salvucci M; Sancetta R; Sica S; Spadano R; Stagno F; Tiribelli M; Tomassetti S; Trabacchi E; Bonifacio M; Breccia M; Castagnetti F; Pane F; Russo D; Saglio G; Soverini S; Vigneri P; Rosti G
    Blood Adv; 2019 Dec; 3(24):4280-4290. PubMed ID: 31869412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.
    Mughal TI; Lion T; Abdel-Wahab O; Mesa R; Scherber RM; Perrotti D; Mauro M; Verstovsek S; Saglio G; Van Etten RA; Kralovics R
    Hematol Oncol; 2018 Dec; 36(5):740-748. PubMed ID: 30074634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
    Bisen A; Claxton DF
    Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and molecular monitoring update in chronic myeloid leukemia management.
    Sorel N; Cayssials É; Brizard F; Chomel JC
    Ann Biol Clin (Paris); 2017 Apr; 75(2):129-145. PubMed ID: 28377326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
    Mahon FX
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):101-103. PubMed ID: 30845112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.